Publications by authors named "T Isei"
"Wound, Pressure Ulcer, and Burn Guidelines-5: Guidelines for the management of lower leg ulcers and varicose veins, second edition" is revised from the first edition, which was published in the Japanese Journal of Dermatology in 2011. The guidelines were drafted by the Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee delegated by the Japanese Dermatological Association and intend to facilitate physicians' clinical decisions in preventing, diagnosing and management of lower leg ulcers and varicose veins. We updated all sections by collecting documents published since the publication of the first edition.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the genetic changes in extramammary Paget disease (EMPD), specifically looking at CDKN2A and MTAP alterations and their impact on disease progression.
- Researchers analyzed 24 invasive/metastatic EMPD cases using immunohistochemistry and DNA sequencing, finding that p16 expression was mostly preserved in early-stage tumors but significantly lost in invasive and metastatic stages.
- The study confirmed CDKN2A deletions in all five metastatic cases tested, suggesting that loss of p16 expression and CDKN2A alterations are common in aggressive forms of EMPD.
Avelumab, a programmed cell death ligand 1 blocking antibody, was approved for its first indication in Japan in September 2017 to treat unresectable Merkel cell carcinoma (MCC). Given that the pivotal JAVELIN Merkel 200 study only included a few Japanese patients, this post-marketing surveillance (PMS) evaluated the safety and effectiveness outcomes of patients with MCC who received avelumab in general clinical practice in Japan. This prospective, non-comparative, multicenter PMS included data from all patients with unresectable MCC who received avelumab between November 22, 2017 (avelumab launch date) and October 31, 2019.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the effectiveness of salvage therapies in Japanese patients with advanced acral melanoma (AM) after they failed PD-1 monotherapy, a common treatment for melanoma.
- 108 patients were analyzed, receiving various treatments such as ipilimumab, nivolumab plus ipilimumab, or cytotoxic chemotherapy, with varying objective response rates (ORR) and overall survival (OS) outcomes.
- Results indicated that while the combination of nivolumab and ipilimumab showed the longest median OS, it was not significantly more effective than other treatments, and nail apparatus melanoma patients had poorer survival outcomes compared to those with palm and sole melanoma.
Article Synopsis
- Anti-PD-1 immunotherapy is less effective for Asian patients with advanced BRAF V600-mutant melanoma, leading researchers to consider alternative first-line treatments.
- A study analyzed treatment outcomes for 336 Asian patients using BRAF/MEK inhibitors, anti-PD-1, and PD-1/CTLA-4 combinations, revealing BRAF/MEKi had the best objective response rates and progression-free survival.
- The results suggested that BRAF/MEKi may be preferred over anti-PD-1 treatments for these patients, particularly in second-line settings, highlighting the need for tailored treatment approaches based on patient demographics.